Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective utilization of circulating tumor DNA testing enables disease monitoring in endometrial and ovarian carcinomas.

Journal of gynecologic oncology - 1 Jan 2025

Jamieson Amy, McConechy Melissa K, Lum Amy, Senz Janine, Dowhy Tanner, Huntsman David G, McAlpine Jessica N

Abstract excerpt

OBJECTIVE: Biomarkers reflecting real-time response to therapy and recurrence are lacking. We assessed the clinical value of detecting cell-free circulating tumor DNA (ctDNA) mutations in endometrial cancer (EC) and ovarian cancer (OC) patients. METHODS: EC/OC patients undergoing primary surgery were consented for tissue banking and 2-year serial blood draws. Tumor tissue DNA and plasma ctDNA underwent next...

Topics

Join the communities discussing this publication.

Biomarkers, Tumor
CA-125 Antigen
Circulating Tumor DNA
Endometrial Neoplasms
High-Throughput Nucleotide Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Neoplasm Recurrence, Local

Neoplasm Staging

Ovarian Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38909641
DOI: 10.3802/jgo.2025.36.e5
PMCID: PMC11791001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective utilization of circulating tumor DNA testing enables disease monitoring in endometrial and ovarian carcinomas.PMID 38909641Read ↗

Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.Semantic proximity Read ↗

Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.Semantic proximity Read ↗

Utility of Circulating Tumor DNA for Detection and Monitoring of Endometrial Cancer Recurrence and ProgressionSemantic proximity Read ↗

Prognostic value of assessing ctDNA in patients with endometrial carcinoma - an international multicenter study.Semantic proximity Read ↗

Circulating tumor DNA as a prognostic marker in high-risk endometrial cancerSemantic proximity Read ↗

Circulating Tumor DNA (ctDNA) and Its Role in Gynecologic Malignancies.Semantic proximity Read ↗

High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer.Semantic proximity Read ↗

Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.Semantic proximity Read ↗

Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients.Semantic proximity Read ↗

Utility of circulating tumor DNA for detection and monitoring of endometrial cancer recurrence and progressionSemantic proximity Read ↗

Sensitive Detection of Gynecological Cancer Recurrence Using Circulating Tumor DNA and Digital PCR: A Comparative Study with Serum Biochemical Markers.Semantic proximity Read ↗

Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.